
Adverum Biotechnologies Investor Relations Material
Latest events

Status Update
Adverum Biotechnologies

Q2 2025
12 Aug, 2025

Corporate Presentation
15 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Adverum Biotechnologies Inc
Access all reports
Adverum Biotechnologies Inc, originally known as Avalanche Biotechnologies Inc, is a clinical-stage gene therapy company based in Redwood City, California. Focused on addressing unmet medical needs, the company targets serious ocular and rare diseases, including wet age-related macular degeneration (wet AMD). It leverages its proprietary intravitreal (IVT) platform to develop durable, single-administration therapies intended to be delivered in physicians' offices. This approach aims to transform the standard of care for highly prevalent ocular diseases by eliminating the need for frequent ocular injections. The company is headquartered in Redwood City, California, and its shares are listed on the Nasdaq.
Key slides for Adverum Biotechnologies Inc


Status Update
Adverum Biotechnologies Inc


Corporate Presentation
Adverum Biotechnologies Inc
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
ADVM
Country
🇺🇸 United States